Last quarter (Q ), THC Farmaceuticals's total revenue was $2.46K, a decrease of -45.46% from the same quarter last year. In Q, THC Farmaceuticals's net income was $-2.79K. See THC Farmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Sep 14	Sep 13	Sep 12	Sep 11	Sep 10
Total Revenue	$ 12.24K	$ 19.03K	$ 21.64K	$ 30.58K	$ 34.16K	$ 29.15K
Cost of Revenue	-	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	-	-	$ 21.64K	$ 30.58K	$ 34.16K	$ 29.15K
Operating Expense	$ 19.95K	$ 43.05K	$ 41.23K	$ 54.11K	$ 57.91K	$ 31.98K
Operating Income	$ -7.72K	$ -24.02K	$ -19.59K	$ -23.53K	$ -23.75K	$ -2.83K
Net Non Operating Interest Income Expense	-	$ -6.68K	$ -4.25K	$ -1.60K	$ -4.61K	$ -3.60K
Other Income Expense	-	-	-	$ -14.56K	-	-
Pretax Income	$ -7.72K	$ -30.70K	$ -23.84K	$ -39.69K	-	-
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -7.72K	$ -30.70K	$ -23.84K	$ -39.69K	$ -28.36K	$ -6.43K
Basic EPS	$ >-0.01	$ -0.01	$ -0.01	$ -0.01	$ -0.01	$ -0.01
Diluted EPS	$ >-0.01	$ -0.01	$ -0.01	$ -0.01	$ -0.01	$ -0.01
Basic Average Shares	$ 58.64M	$ 8.97M	$ 8.97M	$ 8.97M	$ 8.97M	$ 5.33M
Diluted Average Shares	$ 58.64M	$ 8.97M	$ 8.97M	$ 8.97M	$ 8.97M	$ 5.33M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 19.95K	$ 43.05K	$ 41.23K	$ 54.11K	$ 57.91K	$ 31.98K
Net Income From Continuing And Discontinued Operation	$ -7.72K	$ -30.70K	$ -23.84K	$ -39.69K	$ -28.36K	$ -6.43K
Normalized Income	$ -7.72K	$ -30.70K	$ -23.84K	$ -25.14K	$ -28.36K	$ -6.43K
Interest Expense	-	$ 6.68K	$ 4.25K	$ 1.60K	$ 4.61K	$ 3.60K
EBIT	$ -7.72K	$ -24.02K	$ -19.59K	$ -38.09K	$ -23.75K	$ -2.83K
EBITDA	$ -6.76K	$ -23.42K	$ -18.54K	$ -36.66K	$ -17.28K	$ -1.21K

Currency in USD

THC Farmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing